The mTOR inhibitor everolimus suppresses proliferation, metabolic activity and collagen synthesis of human fibroblasts in vitro and exerts antifibrogenic effects in vivo

Abstract

Fibrosclerotic and fibroproliferative diseases remain a therapeutic challenge in dermatology. Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is approved for prophylaxis against allograft rejection, treatment of renal cell carcinoma, and use as a drug-eluting stent¹. Interestingly, rapamycin improved skin stiffness and mobility in a patient with systemic sclerosis (SSc)². A randomized, single-blind pilot study confirmed that rapamycin has beneficial effects on the modified Rodnan skin thickness score and on the patient's global assessment in SSc³.

This article is protected by copyright. All rights reserved.

http://ift.tt/2miBfln